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cells showed low to moderate integrin α-4 and strong β-1 but 
no definite β-7 expression in vitro and in situ. Increased brain 
endothelial integrin α-4 expression was observed in active MS 
lesions in situ and after angiogenic stimulation in vitro. Expo-
sure of cultured primary brain endothelial cells to recombi-
nant sVCAM-1 significantly increased their permeability to 
the soluble tracer dextran, which was paralleled by formation 
of actin stress fibres and reduced staining of tight junction-
associated molecules. Soluble VCAM-1 was also found to 
activate Rho GTPase and p38 MAP kinase. Chemical inhibi-
tion of these signalling pathways partially prevented sVCAM-
1-induced changes of tight junction arrangement. Importantly, 
Abstract Human brain microvascular endothelial cells form-
ing the blood–brain barrier (BBB) release soluble vascular 
cell adhesion molecule-1 (sVCAM-1) under inflammatory 
conditions. Furthermore, sVCAM-1 serum levels in untreated 
patients with multiple sclerosis (MS) correlate with a break-
down of the BBB as measured by gadolinium-enhanced MRI. 
To date, it is unknown whether sVCAM-1 itself modulates 
BBB permeability. Here, we provide evidence that human brain 
endothelium expresses integrin α-4/β-1, the molecular binding 
partner of sVCAM-1, and that sVCAM-1 directly impairs BBB 
function by inducing intracellular signalling events through 
integrin α-4. Primary human brain microvascular endothelial 
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natalizumab, a neutralising recombinant monoclonal antibody 
against integrin α-4 approved for the treatment of patients with 
relapsing–remitting MS, partially antagonised the barrier-dis-
turbing effect of sVCAM-1. In summary, we newly character-
ised sVCAM-1 as a compromising factor of brain endothelial 
barrier function that may be partially blocked by the MS thera-
peutic natalizumab.
Keywords Multiple sclerosis · Blood–brain barrier · 
Endothelial cell · Integrin alpha4 · Vascular cell adhesion 
molecule-1 · Natalizumab
Abbreviations
BBB  Blood–brain barrier
Gd  Gadolinium
HBMEC  Human brain microvascular endothelial cells
HUVEC  Human umbilical vein endothelial cells
IFN-β  Interferon β
MS  Multiple sclerosis
NATA  Natalizumab
PBMC  Peripheral blood mononuclear cells
sVCAM-1  Soluble vascular cell adhesion molecule-1
VLA-4  Very late antigen-4
Introduction
Cell-bound vascular cell adhesion molecule-1 (VCAM-1, 
CD106) allows human brain microvascular endothelium to 
control immune cell trafficking across the blood–brain bar-
rier (BBB). It is upregulated in inflammatory-active brain 
lesions of patients with multiple sclerosis (MS), a chronic 
degenerative autoimmune disease of the CNS [1, 16, 45]. 
Endothelial VCAM-1 serves as a binding partner for inte-
grin α-4/β-1 (very late antigen-4, VLA-4) on peripheral 
blood mononuclear cells (PBMC), as it does for α-4/β-7 
heterodimers to a lesser extent [5, 17]. This molecular 
interaction enables PBMC to firmly adhere to the vessel 
wall after rapid activation of integrin α-4-mediated intracel-
lular signalling cascades, allowing subsequent immune cell 
extravasation [39].
A soluble form of VCAM-1 (sVCAM-1) is shedded 
from the surface of brain endothelial cells upon inflamma-
tory activation [24]. In vitro, sVCAM-1 blocked leukocyte 
adhesion to activated human brain endothelium. Soluble 
VCAM-1 was therefore considered as an inflammation-
limiting factor at the inflamed BBB [25]. Clinical studies in 
MS patients treated with recombinant interferon-β (IFN-β), 
which moderately reduces relapse rate, disability progres-
sion and MRI disease activity [9], seemed to support this 
hypothesis: IFN-β therapy increased sVCAM-1 serum lev-
els, which correlated with a reduction of gadolinium (Gd)-
enhancing MRI brain lesions, indicating less inflammatory 
disease activity at the BBB [12, 20, 38]. Together, these in 
vitro and clinical studies suggested a local anti-inflamma-
tory effect of sVCAM-1 at the human BBB due to an inhi-
bition of immune cell extravasation [14].
In addition to their regulation of immune cell trafficking, 
brain endothelial cells strictly govern the exchange of sol-
ute and soluble factors across the BBB. Endothelial molec-
ular control mechanisms include active transendothelial 
transport systems and tight junctions. The latter are highly 
dynamic trans-membrane protein complexes, tightly seal-
ing the interendothelial clefts [46]. Extravasation of soluble 
factors such as albumin or immunoglobulins is a direct cor-
relate of BBB dysfunction as visualised by Gd-enhanced 
MR imaging [23, 30]. Interestingly, sVCAM-1 serum levels 
in MS patients not receiving IFN-β treatment were shown 
to positively correlate with the presence of Gd-enhancing 
lesions on brain MRI scans and with clinical disease activ-
ity in a majority of studies [15, 18, 19, 22, 36, 37]. This 
seems to contradict the IFN-β studies cited above where 
an inverse correlation between sVCAM-1 serum levels and 
MRI disease activity was observed. The mechanisms under-
lying these divergent findings are unknown. Furthermore, it 
currently remains unknown whether sVCAM-1 exerts any 
direct effect on brain endothelial barrier function.
So far, it is unknown whether undiseased human brain 
endothelial cells or those in MS CNS lesions express the 
established binding partners of sVCAM-1, i.e. integrin α-4 
heterodimers. An expression of integrin α-4 by human brain 
endothelium in situ was previously described in activated 
glioma endothelial cells [33]. Furthermore, expression 
of integrin α-4/β-1 and of α-4/β-7 was reported in human 
umbilical vein endothelial cells (HUVEC) and in adult 
human synovial membrane endothelium from patients with 
rheumatoid arthritis [6, 29]. VLA-4 expression was further-
more documented in adult human dermal microvascular 
endothelial cells [26]. Endothelial integrin α-4 expression 
was lower than integrin β-1 expression in these endothelial 
cell types, but could be upregulated by pro-inflammatory 
stimulation with TNF-α [6, 32]. HUVEC binding to recom-
binant VCAM-1 and to the extracellular matrix protein 
fibronectin was found to be mediated by VLA-4 [26, 29]. 
Furthermore, sVCAM-1 was shown to activate p38 MAP 
kinase and focal adhesion kinase in HUVEC via integrin 
α-4, which promoted HUVEC migration in vitro and angio-
genesis in mouse corneas in vivo [32]. Effects of sVCAM-1 
on the barrier function of integrin α-4-positive endothelial 
cells have not been reported to date.
Here, we investigated the expression of sVCAM-
1-binding integrins on adult human brain endothelium both 
under non-inflammatory and inflammatory conditions, and 
studied whether and how sVCAM-1 affects the barrier 
function of cultured primary human brain microvascular 
endothelium.




Cryopreserved early post-mortem autopsy specimens from 
normal human brain and spinal cord of three donors who 
had died from non-neurological diseases and cryopreserved 
brain biopsy samples from two donors without pathologi-
cal changes in the biopsy material used for this study were 
from the brain bank at the Department of Neuropathology 
in Würzburg and used for research purposes as approved by 
the local Ethics Committee of the Faculty of Medicine at 
the University of Würzburg.
Furthermore, brain tissue from seven cases with clini-
cally diagnosed and pathologically confirmed MS (3 
female, median disease duration 22 years, median age at 
death 60 years, range 43–90) and four non-neurological 
control cases (2 female, median age at death 82 years, 
range 73–91) was obtained by rapid autopsy (median post-
mortem delay 6 h, range 4–18 h) and immediately frozen 
in liquid nitrogen (The Netherlands Brain Bank, Amster-
dam, coordinator Dr. Huitinga). The Netherlands Brain 
Bank received permission to perform autopsies for the use 
of tissue and for access to medical records for research 
purposes from the Ethical Committee of the VU University 
Medical Centre, Amsterdam, The Netherlands. Supraten-
torial white matter MS and control tissue samples were 
selected on the basis of post-mortem MRI. All patients 
and controls, or their next of kin, had given informed con-
sent for autopsy and use of their brain tissue for research 
purposes. MS lesion activity was classified based on the 
expression of myelin and inflammatory cells, defined by 
staining for proteolipid protein and HLA-DR as described 
before [13, 27].
Brain endothelial cells
Cryopreserved single-donor primary human brain micro-
vascular endothelial cells (HBMEC) isolated from nor-
mal human brain and reported to be mycoplasma nega-
tive by the provider were purchased from Cell Systems 
Corp. (Kirkland, WA, USA) at passage 2. Preparations 
were analysed from nine different donors. Before experi-
mental use, each preparation was extensively character-
ised for potential contamination by other cell types and 
for expression of tight junction-associated molecules as 
previously described [8]. The endothelial cell fraction 
was >98 % in all samples. A well-characterised immor-
talised HBMEC line (HBMECKim) was kindly provided 
by Kim [43]. Both cell types were plated on culture 
dishes (Nunc, Roskilde, Denmark) coated as indicated 
and cultured at 37 °C/5 % CO2 in Medium 199 (Lonza, 
Cologne, Germany) containing 10 % foetal calf serum 
(FCS; Biochrom, Berlin, Germany), endothelial cell 
growth supplement (20 μg/mL; Sigma-Aldrich, Schnell-
dorf, Germany), heparin (100 μg/mL; Sigma-Aldrich), 
amphotericin B (250 μg/mL), gentamycin (50 μg/mL), 
penicillin (50 U/mL) and streptomycin (50 μg/mL; all 
from Invitrogen, Karlsruhe, Germany). All primary cell 
preparations as well as HBMEC were mycoplasma nega-
tive, as revealed by a commercial PCR-based myco-
plasma detection kit (PK-CA91; PromoKine, Heidelberg, 
Germany). Primary endothelial cells were used from pas-
sage 4 to 6 for experiments, immortalised endothelial 
cells from passage 20 to 30.
Immunohistochemistry
For immunofluorescence histochemistry, 5-µm cryostat 
sections were blocked with a donkey serum solution and 
incubated with primary antibodies (Abs) at 4 °C over-
night. Tested monoclonal mouse Abs against integrin α-4 
included clones 2B4, 7.2R (both from R&D, Karlsruhe, 
Germany) and L25 (BD Biosciences, Heidelberg, Ger-
many). For staining of integrin β-1, we used a rat mono-
clonal Ab (clone mAb13, BD Biosciences), and for integ-
rin β-7, we employed the mouse monoclonal Ab FIB504 
(BD Biosciences). Rabbit polyclonal Abs against von 
Willebrand factor (vWF; DAKO, Hamburg, Germany) 
or laminin (MP Biomedicals, Eindhoven, Netherlands) 
were used to stain the brain vasculature. A biotinylated 
antibody against HLA-DR (clone LN3) was used to stain 
immune cells. Isotype-matched control Abs were from 
BD Biosciences. Fluorescence-conjugated secondary Abs 
were from Dianova (Hamburg, Germany) and incubated 
for 1 h.
For bright field stainings, sections were deparaffinised 
and treated with 0.3 % H2O2 in methanol for 20 min to 
reduce endogenous peroxidase activity. Antigen retrieval 
was achieved by incubating the sections at 100 °C in Tris–
EDTA buffer (10–0.5 mM, pH 9.0) for 10 min. After wash-
ing with phosphate-buffered saline (PBS), sections were 
treated with 0.1 % saponin in PBS, washed, and subse-
quently incubated with the same primary Abs as used for 
immunofluorescence histochemistry in PBS overnight at 
4 °C. Slides were then washed and incubated with EnVi-
sion + Dual Link reagent (DAKO, Glostrup, Denmark) 
for 30 min followed by visualisation with the peroxidase 
substrate diaminobenzidine (DAB) (DAKO, Glostrup, Den-
mark). After a short rinse in tap water, sections were incu-
bated with haematoxylin for 1 min and extensively washed 
with tap water for 10 min. Finally, sections were dehy-
drated with ethanol followed by xylene and mounted with 
Entellan (Merck, Darmstadt, Germany).
Samples were analysed with an Olympus IX-70 inverted 
system microscope with IX-FLA observation attachment 
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for fluorescence imaging, with a Zeiss LSM 780 confocal 
microscope or with a Leica DM6000 microscope (Leica 
Microsystems, Heidelberg, Germany).
Flow cytometry
HBMEC were grown to subconfluency on 6-well plates 
and then stimulated as indicated. Vascular endothelial 
growth factor-165 (VEGF165) was purchased from Pep-
roTech Inc. (Hamburg, Germany) and TNF-α was from 
R&D Systems. Thereafter, cells were detached with 
500 μL Accutase™ (PAA Laboratories, Coelbe, Ger-
many), washed and incubated with uncoupled mouse anti-
integrin α-4 (clone L25), PE-coupled mouse anti-integrin 
β-1 (clone MAR4, BD Biosciences), PE-coupled mouse 
anti-integrin β-7 (clone FIB504, BD Biosciences) or 
isotype-matched control Abs (all from BD Biosciences) 
for 30 min at 4 °C. For integrin α-4 staining, cells were 
additionally incubated with a FITC-labelled secondary 
Ab against mouse IgG (R&D, Karlsruhe, Germany) after 
a washing step. Fluorescence-activated cell sorting analy-
sis was performed on a FACSCalibur (BD Biosciences). 
For all integrin stainings including integrin β-7, human 
PBMC, freshly isolated by Ficoll gradient centrifugation 
according to a standard protocol, were used as a positive 
control.
Boyden chamber assay
For paracellular permeability assays, 1 × 105 per well 
cells were seeded on rat collagen-coated (100 µg/mL) fil-
ters (0.4 µm pore size) of a 24-well Boyden chamber sys-
tem (Corning Life Sciences, Wiesbaden, Germany) and 
grown to confluency which usually took 3 days. Conflu-
ency was assessed by DAPI staining of filters grown in 
parallel. Part of the cells was pre-incubated with natali-
zumab (Biogen Idec, Ismaning, Germany) or a corre-
sponding IgG4κ isotype control (Sigma-Aldrich) for 1 h 
as indicated. Stimulations were performed with recom-
binant human VCAM-1 or ICAM-1 (R&D Systems) 
or TNF-α plus interferon-γ (IFN-γ, R&D Systems) for 
the indicated durations. After stimulation, medium was 
removed in the upper and lower chambers and replaced 
by HEPES buffer. To trace cell permeability, 1 mg/mL 
FITC-dextran 3000 was added to the upper chambers and 
relative fluorescence in the lower chambers was measured 
90 min later, using a Fluoroskan Ascent® (Thermo Elec-
tron Corporation, Dreieich, Germany) microplate fluo-
rometer. Dextran concentrations in the lower chambers 
were determined using a dextran standard curve. To max-
imise assay precision, experiments were performed in 12 
wells per stimulation condition.
Immunocytochemistry
For immunocytochemical stainings of tight junction-asso-
ciated molecules, cells were grown on 2 % gelatin-coated 
24-well plates and stimulated as indicated. Rho-associated 
kinases inhibitor Y-27632 and p38 inhibitor SB203580 
were from Calbiochem—Merck4Biosciences (Darmstadt, 
Germany). Then cells were fixed with 3.7 % formalin for 
10 min, permeabilised with 0.1 % Triton X-100 for 6 min, 
and washed with Dulbecco’s PBS. Unspecific Ab bind-
ing was blocked by 5 % BSA (Sigma-Aldrich) in PBS for 
60 min at room temperature. Subsequently, primary Abs to 
zonula occludens (ZO)-1 (rabbit polyclonal, Invitrogen), 
occludin (mouse monoclonal, clone OC-3F10, Invitro-
gen) and junctional adhesion molecule (JAM)-A (mouse 
monoclonal, clone M.Ab.F11, AbD Serotec, Düsseldorf, 
Germany) were incubated for 60 min at room tempera-
ture. After washing, an appropriate Cy3-coupled secondary 
Ab was incubated for another hour at room temperature. 
After a further washing step, nuclei were counterstained 
with DAPI. After a final washing step, an antifading agent 
(Dabco, Merck, Germany) was added. Negative controls 
were performed by omitting the primary Abs and by stain-
ings with isotype-matched control Abs (data not shown). 
The stainings were analysed by an Olympus IX-70 inverted 
system microscope with IX-FLA observation attachment 
for fluorescence imaging. All analyses were performed by 
blinded observers directly at the microscope and not from 
electronic images.
Western blotting
For generation of whole cell protein extracts, cells grown 
to subconfluency in 25 cm2 flasks were stimulated as indi-
cated, washed with icecold PBS and scraped into radio-
immunoprecipitation assay (RIPA) buffer composed of 
50 mM HEPES, 125 mM NaCl, 1 % Nonidet P40, 1 mM 
EDTA pH 7.4 and 1 × Roche COMPLETE® protease 
inhibitor mix (Roche Diagnostics GmbH, Mannheim, Ger-
many). Samples were shaken vigorously for 30 min, and 
then centrifuged at 18,000g for 15 min at 4 °C. Superna-
tants were subjected to Western blot analysis. Primary Abs 
were used against phospho-p38 (cat.-no. 9211, Cell Signal-
ing, Danvers, MA, USA), phospho-ERK (cat.-no. sc-7383, 
Santa Cruz, Heidelberg, Germany) or phospho-JNK (cat.-
no. sc-6254, Santa Cruz). Appropriate peroxidase-coupled 
secondary Abs were employed with a standard enhanced 
chemoluminescence system (Amersham, Arlington 
Heights, IL, USA). After peroxidase inactivation, mem-
branes were reprobed with Abs against total p38 (cat.-no. 
9212, Cell Signaling), ERK (cat.-no. sc-94, Santa Cruz) or 
JNK (cat.-no. sc-474, Santa Cruz).
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Rho activation assay
Rho activation assays were performed using the Rho Acti-
vation Assay Kit from Millipore (Schwalbach/Ts., Ger-
many) according to the instructions of the manufacturer. 
In brief, active, GTP-bound Rho was isolated from cell 
extracts using a GST-tagged fusion protein corresponding 
to residues 7–89 of mouse Rhotekin rho-binding domain 
and bound to glutathione–agarose, and subsequently 
detected by immunoblot analysis using anti-Rho.
Statistical analysis
For statistical analysis of the dextran permeability assays, 
a Kruskal–Wallis test was followed by Dunn’s post test 
for multiple comparisons. Calculations were performed 
with GraphPad PRISM 4 software (GraphPad Software, La 
Jolla, CA).
Results
Low to moderate normal brain endothelial integrin  
α‑4 expression in situ and in vitro
Expression of integrin α-4 and its heterodimerisation 
partners β-1 and β-7 was previously described in various 
non-CNS human endothelial cell types [6, 26, 29]. In con-
trast, integrin α-4 expression was not previously reported 
in undiseased adult human brain endothelium. To investi-
gate integrin expression by brain endothelial cells in situ, 
we performed immunohistochemical stainings on cryostat 
sections of early post-mortem normal human brain and spi-
nal cord. Moderate integrin α-4 expression was detected in 
310/400 (77.5 %) analysed vWF-positive blood vessels of 
various sizes in tissue samples from all three tested donors 
(examples shown in Fig. 1a). In contrast to only moderate, 
non-uniform integrin α-4 expression, strong endothelial 
β-1 expression was uniformly observed in all vWF-positive 
blood vessels of all donors (examples shown in Fig. 1b). 
Accordingly, all integrin α-4-positive vessels were β-1 pos-
itive (example shown in Fig. 1c). No endothelial integrin 
β-7 expression was detected in situ (data not shown).
To further study the subcellular localisation of integrin 
α-4 in human brain endothelium in situ, we next investi-
gated cryopreserved brain biopsy specimens from two 
donors without pathological changes in their biopsies, as 
revealed by extensive neuropathological evaluation. The 
expression of integrin α-4 was found to be mainly restricted 
to the luminal membranes and weaker detectable in the 
abluminal membranes (Fig. 1d).
To explore integrin expression on human brain endothe-
lium in vitro, we next performed flow cytometric stainings 
of a well-characterised immortalised human brain micro-
vascular endothelial cell line and of highly pure single-
donor primary cell preparations, in particular the latter 
showing a well-preserved expression of tight junctions’ 
molecules and an intact paracellular barrier function [8, 
21]. In line with the in situ stainings, strong permanent 
integrin β-1 and no β-7 expression were uniformly detected 
in all tested cell preparations (examples shown in Fig. 2a, 
b). Importantly, low to moderate integrin α-4 expression 
was detected in the immortalised cell line and 6/9 tested 
single-donor primary cell preparations (examples shown 
in Fig. 2c). Of note, integrin α-4 was not permanently 
expressed under basic culture conditions in vitro, but inter-
mittently undetectable in the majority of positive prepara-
tions including the cell line. Integrin α-4 was found to be 
either detectable or undetectable after thawing and seed-
ing of a cell vial but the status of integrin α-4 expression 
was usually found not to change during the same passage 
under non-stimulated conditions. In accordance with pre-
vious reports on other endothelial cell types [6, 32], inte-
grin α-4 expression was generally lower than β-1 expres-
sion. Furthermore, it varied considerably between different 
batches of an individual single-donor primary cell prepa-
ration (Fig. 2d), however, not within single experiments, 
and it varied between different preparations (Fig. 2e). Both 
immunohistochemical detection of integrin α-4 on vWF-
positive brain endothelium in situ and detection in the 
immortalised cell line provided evidence that integrin α-4 
detection in the cultured primary cell preparations could 
at least not solely be attributed to potential contamination 
with other cell types, which was additionally excluded by 
extensive control stainings of each cell preparation as pre-
viously described [8]. Together, these in situ and in vitro 
experiments indicated low to moderate integrin α-4, strong 
β-1 and no β-7 expression by adult human brain endothelial 
cells in situ and in vitro.
Increased endothelial integrin α‑4 expression 
after angiogenic stimulation in vitro and in active MS 
brain lesions
In contrast to integrin β-1, the expression of integrin α-4 
by cultured brain endothelium was found to be unsta-
ble within individual cell preparations. We therefore next 
sought to identify factors modulating its expression. A 
comparison of proliferating and confluent primary brain 
endothelial cells, which were cultured in parallel, did not 
reveal different integrin α-4 expression levels on the cell 
surface (Fig. 3a). As shown in Fig. 3b, pro-inflammatory 
stimulation with TNF-α did not reveal a significant effect 
on integrin α-4 expression either, which was in contrast to 
previous reports on other endothelial cell types, where an 
upregulation of integrin α-4 expression was observed after 
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Fig. 1  Human CNS microvas-
cular endothelial cells show 
moderate integrin α-4 and 
strong β-1 expression in situ. 
Cryopreserved early post-
mortem normal human brain 
tissue was double-stained for 
integrin α-4 (red) and for vWF 
(green) as an endothelial marker 
(a), integrin β-1 (red) and 
vWF (green) (b) or for integrin 
α-4 (red) and β-1 (green) (c). 
Representative for normal brain 
and spinal cord samples from 
three different donors. d To 
further study the subcellular 
localisation of integrin α-4, 
cryopreserved brain biopsy 
samples from two donors with-
out evidence for pathological 
changes, as revealed by detailed 
neuropathological evaluation, 
were analysed by confocal 
microscopy. Integrin α-4 is 
shown in red, vWF in green. 
Yellow in the merge images 
indicates co-localisation of the 
investigated molecules. Scale 
bars 25 µm




























































































































Fig. 2  Brain endothelial cells show low to moderate integrin α-4 and 
strong β-1 but no β-7 expression in vitro. Flow cytometric analysis 
of integrin β-1 (a), β-7 (b) and α-4 (c) expression by the immortal-
ised human brain endothelial cell line HBMECKIM and cultured 
single-donor primary cell preparations, or human PBMC as a posi-
tive control for integrin β-7 staining (shown in b). While integrin 
β-1 was strongly and permanently detected in all cell preparations, 
integrin α-4 was intermittently undetectable in the majority of prepa-
rations (see text); only positive examples shown in c. Note the dif-
ferent X axis labelling in a versus b and c. d Variability of integrin 
α-4 expression between different batches of an exemplary individual 
single-donor primary cell preparation under identical basic culture 
conditions as described in “Materials and methods” without previ-
ous starvation, forming a subconfluent monolayer (n = 7). Passage 
numbers are indicated as passage 4 or 5 (p4 or p5, respectively). e 
Variation of integrin α-4 expression levels between six different inte-
grin α-4-positive single-donor primary cell preparations under identi-
cal basic culture conditions at different passages, referred to as p3, p5 
and p6, respectively
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TNF-α stimulation [6, 32]. Stimulation with IFN-γ, IFN-β, 
IL-6 and TGF-β did not alter integrin α-4 expression either 
(data not shown). In contrast, stimulation with recombinant 
VEGF165, a variant of VEGF-A, induced a variable upregu-
lation of integrin α-4 expression by a mean of 23 % (range 
+0.3 % [no effect in one single preparation] to +45.2 %, 
one example shown in Fig. 3c), being in line with previous 
reports where endothelial VLA-4 was found to be involved 
in angiogenesis [32, 41]. While integrin β-1 expression lev-
els did not change after cytokine stimulation, integrin β-7 
remained undetectable (data not shown). Although not for-
mally analysed, increasing passage numbers did not sys-
tematically alter integrin α-4 expression levels in our obser-
vation. In summary, we identified VEGF as one cytokine 
upregulating the expression of integrin α-4 on cultured pri-
mary human brain endothelial cells.
VEGF is strongly expressed in inflammatory-active MS 
lesions [35, 40], its serum levels were found to be increased 
during relapses [44], and astrocyte-derived VEGF mediated 
a disruption of the BBB in animal models of the disease [3, 
4]. We therefore next investigated endothelial integrin α-4 
expression in MS brain lesions. A strong vascular expres-
sion of integrin α-4 was observed in inflammatory-active 
demyelinating lesions, whereas control tissue displayed 
only moderate immunoreactivity to integrin α-4 (Fig. 4a, 
b). In contrast, strong vascular expression of integrin β-1 
was found to be downregulated in active MS lesions as 
compared to control tissue, although it remained clearly 
detectable in active MS lesions (Fig. 4c). While integrin 
β-7 had not been detectable in immunofluorescence stain-
ings of normal human brain and in cultured brain endothe-
lial cells as reported, very faint and diffuse anti-integrin β-7 
DAB staining of vessel walls was observed both in control 
tissue and active MS lesions. These stainings did not pro-
vide definite evidence for an expression of integrin β-7 by 
brain endothelial cells in situ in our interpretation. In sum-
mary, endothelial integrin α-4 was upregulated while integ-
rin β-1 was partially downregulated in inflammatory-active 
MS brain lesions as compared to control tissue.
Soluble VCAM‑1 increases brain endothelial 
permeability via integrin α‑4 and alters actin  
and tight junction morphology
Having studied the expression of sVCAM-1-binding inte-
grins on adult brain endothelial cells, we next evaluated 
whether sVCAM-1 affects their paracellular barrier func-
tion. Boyden chamber permeability assays using dextran 
3000 as a tracer revealed an increase of dextran permeabil-
ity after stimulation of integrin α-4-positive primary brain 
endothelium with recombinant sVCAM-1 for 1 h (Fig. 5a). 
This increase of paracellular permeability was paralleled 
by a reorganisation of the actin cytoskeleton with forma-
tion of stress fibres. Furthermore, we found reduced cell 
border staining of the tight junction-associated proteins 
occludin, JAM-A and ZO-1 (Fig. 5b). All immunocyto-
chemical stainings were evaluated by blinded investigators. 
Both sVCAM-mediated loss of barrier function and altera-
tion of tight junction morphology principally resembled the 
pro-inflammatory action of TNF-α and IFN-γ, with particu-
larly morphological changes of endothelial cells being less 
pronounced after sVCAM-1 stimulation. While sVCAM-1 
exerted a barrier-disturbing effect already at a concentra-
tion of 50 ng/mL in our in vitro system, a 100-fold higher 
concentration of sICAM-1, another cell adhesion molecule 
of the immunoglobulin superfamily, did not alter endothe-
lial barrier function (Fig. 5c). Importantly, blocking integ-
rin α-4 by the clinically well-established humanised neu-
tralising monoclonal Ab natalizumab partially inhibited the 






































Fig. 3  Upregulation of brain endothelial integrin α-4 expression 
after angiogenic stimulation in vitro. a Flow cytometric comparison 
of integrin α-4 expression on proliferating versus confluent primary 
human brain endothelial cells. Analysis of integrin α-4 expression 
after stimulation of subconfluent primary brain endothelium with 
10 ng/mL TNF-α (b) or 10 ng/mL VEGF165 (c) for 24 h. Each con-
dition representative of at least five independent experiments with 
different integrin α-4-positive primary brain endothelial cell prepara-
tions
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Fig. 4  Expression of brain 
endothelial integrins α-4, β-1 
and β-7 in human active white 
matter lesions in post-mortem 
material of MS cases compared 
to controls without clinical 
and autoptic evidence for a 
pathological CNS condition. 
MS lesion activity was char-
acterised by myelin staining 
against proteolipid protein and 
against HLA-DR to visualise 
mononuclear immune cells and 
activated microglia (data not 
shown). a Immunoreactivity for 
integrin α-4 (CD49d) is labelled 
in green, HLA-DR (clone LN3) 
in red to visualise immune cells 
and laminin in blue to visualise 
the vascular basement mem-
brane. The right column shows 
merged images. b DAB bright 
field stainings against integrin 
α-4 of samples from different 
cases than those shown in a to 
demonstrate tissue preservation, 
relation of blood vessels to the 
surrounding tissue and regula-
tion of integrin α-4 expression. 
c, d Expression of integrin β-1 
(c) or integrin β-7 (d) in active 
MS lesions versus control tis-
sue, as demonstrated by DAB 
bright field stainings. Repre-
sentative of autoptic samples 
from supratentorial white matter 
of seven different MS cases and 
four controls (1 tissue block per 
case). Scale bars 10 µm (a, b) 
or 50 µm (c, d)



















































































649Acta Neuropathol (2015) 129:639–652 
1 3
(Fig. 5d)—demonstrating that the barrier-disturbing effect 
of sVCAM-1 was at least partially mediated by integrin α-4 
and suggesting a novel protective mode of action of natali-
zumab at the BBB.
Rho GTPase and p38 mediate sVCAM‑1‑induced 
alteration of tight junction morphology
Based on reports that sVCAM-1 may induce VLA-4-me-
diated intracellular signalling events both in mononuclear 
cells [39] and in human endothelial cells [32], we next 
sought to identify intracellular signalling molecules acti-
vated by sVCAM-1 in brain endothelial cells. As actin 
stress fibres were induced by sVCAM-1, we chose Rho 
GTPase, which is critically involved in brain endothelial 
stress fibre formation [2, 28], as one molecule of inter-
est. Based on a report about integrin α-4-transduced p38 
MAP kinase activation in sVCAM-1-stimulated HUVEC 
[32], we furthermore studied activation of MAP kinases. 
We found rapid activation of Rho upon stimulation of pri-
mary HBMEC with sVCAM-1 (Fig. 6a). Furthermore, 
we observed a sustained activation of p38 MAP kinase 
(Fig. 6b) but not of ERK1/2 or JNK (data not shown). 
These experiments indicated rapid activation of Rho and 
sustained activation of p38 MAP kinase by sVCAM-1 in 
adult brain microvascular endothelial cells.
In a last step, we investigated whether the identified 
intracellular signalling molecules mediated the barrier-
disturbing effect of sVCAM-1. Chemical inhibition of 
Rho-associated kinases (ROCK) by Y-27632 or of p38 by 
SB203580 partially prevented sVCAM-1-induced actin 
reorganisation (Fig. 7a) and altered expression of tight 
junction-associated molecules in primary endothelial cells 
(Fig. 7b). These experiments indicated that sVCAM-1-in-
duced tight junction reorganisation was partially mediated 
by the identified sVCAM-1-induced intracellular signalling 
events in primary human brain endothelium.
Discussion
Here we report that non-inflamed adult human brain micro-
vascular endothelium expresses integrin α-4 in situ and 
Fig. 6  Soluble VCAM-1 activates Rho GTPase and p38 MAP kinase 
in brain endothelial cells. a Western blot analysis of Rho activation in 
integrin α-4-positive primary HBMEC after stimulation with 5 µg/mL 
sVCAM-1 for 10 min. b Western blot analysis of p38 MAP kinase 
activation after stimulation with 5 µg/mL sVCAM for the indicated 
durations. Stimulation with 12-O-tetradecanoylphorbol-13-acetate 
(TPA) and ionomycin for 10 min was used as a positive control. Rep-
resentative of four independent experiments with different primary 
cell preparations
Fig. 5  Soluble VCAM-1 increases paracellular permeability of brain 
endothelial cells, which is inhibited by natalizumab, and induces 
actin stress fibre formation and alters tight junction morphology. a 
Analysis of paracellular barrier function by dextran 3000 Boyden 
chamber assays. Stimulation with 5 µg/mL sVCAM-1, or 10 ng/mL 
TNF-α + 100 IU/mL IFN-γ as a positive control for 1 h. All stim-
ulations were performed in dodecaplicates. Mean and SEM of four 
independent experiments with different integrin α-4-positive primary 
HBMEC preparations. Statistical analysis by Kruskal–Wallis test and 
Dunn’s post test for multiple comparisons. b Immunocytochemical 
staining of the tight junction-associated molecules occludin, JAM-A 
and ZO-1, and F-actin staining with Alexa Fluor 488 phalloidin after 
stimulation of primary HBMEC as in a. Representative of four inde-
pendent experiments evaluated by blinded investigators. Scale bar 
25 µm. c Concentration-dependent regulation of integrin α-4 expres-
sion after stimulation with sVCAM-1 or sICAM-1 at the indicated 
concentrations ranging from 5 to 5 µg/mL for 1 h. Mean and SEM 
of a Boyden chamber dextran permeability assay as described in a 
representative of three independent experiments. d Soluble VCAM-
1-induced increase in paracellular permeability is partially inhibited 
by pre-incubation with natalizumab (NATA). Pre-incubation with 
3 µg/mL of either natalizumab, a humanised monoclonal antibody 
against integrin α-4, or IgG4κ as the corresponding isotype control 
for 1 h was followed by addition of 5 µg/mL sVCAM-1 for 1 h. Mean 
and SEM of four independent Boyden chamber dextran permeability 
assay experiments as described in a. Note that y axis does not start 
from zero in c and d
◂
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in vitro. Integrin α-4 was found to be upregulated after 
angiogenic stimulation in vitro and in active demyelinat-
ing MS brain lesions. Integrin α-4/β-1 is an established 
binding partner of sVCAM-1 which gets released from 
brain endothelial cells under inflammatory conditions [25]. 
In our hands, recombinant sVCAM-1 compromised brain 
endothelial barrier function in vitro, which was mediated 
by the induction of intracellular signalling events includ-
ing the activation of Rho GTPase and p38 MAP kinase 
through binding of sVCAM-1 to integrin α-4. While the 
MS therapeutic natalizumab is well known to exert a pro-
tective effect at the BBB by blocking leukocyte adhesion, 
our findings suggest a novel additional protective mode of 
natalizumab action at the BBB by partially inhibiting integ-
rin α-4 on brain endothelial cells.
Our in vitro findings indicate that a positive correla-
tion between sVCAM-1 serum levels and Gd-enhancing 
MRI brain lesions in untreated MS patients, as observed 
by many authors [15, 18, 19, 22, 36, 37], at least partially 
reflect a direct causal relationship between both variables: 
sVCAM-1, which is released from inflammatory-activated 
human brain endothelium [24], could enhance BBB dys-
function in acute MS brain lesions by endothelial autocrine 
stimulation. Accordingly, increased sVCAM-1 serum levels 
in untreated MS patients with active disease would particu-
larly be explained by a sVCAM-1 release from endothe-
lium in inflammatory-active brain lesions. In contrast, an 
elevation of sVCAM-1 serum levels by IFN-β treatment 
could be due to a sVCAM-1 release particularly from vas-
cular beds exposed to very high IFN-β concentrations, i.e. 
near the injection sites, but possibly not mainly the brain. 
However, brain endothelial cells were shown to release 
sVCAM-1 upon IFN-β exposure in vitro, establishing a 
direct causal link between exposure of endothelial cells to 
IFN-β and a release of sVCAM-1 [11, 25]. At IFN-β skin 
injection sites, strong inflammatory immune reactions, pos-
sibly boosting an IFN-β-induced release of sVCAM-1 from 
local endothelial cells, occur frequently. Such inflammatory 
reactions are common even if no externally visible skin 
reactions are present, as demonstrated by a placebo-con-
trolled skin biopsy study [7]. Further following this explan-
atory model of a spatially differential sVCAM-1 release 
in untreated active versus IFN-β-treated MS patients, an 
inverse correlation between sVCAM-1 serum levels and 
Gd-enhancing MRI brain lesions in IFN-β-treated MS 
patients could then be explained by a predominant thera-
peutic effect of sVCAM-1-triggered VLA-4 downregula-
tion on PBMC via ligand–receptor interaction as previously 
demonstrated [31]. This may render them less responsive to 
endothelium-bound VCAM-1 expressed in inflammatory-
active MS brain lesions and therefore reduce inflammatory 
MRI disease activity. Importantly, VLA-4 downregulation 
on PBMC inversely correlated with both sVCAM-1 serum 
levels and with clinical treatment response [42]. Together, 
these findings argue for a predominant sVCAM-1 effect 
on immune as opposed to brain endothelial cells in IFN-
β-treated patients. In summary, we suggest that sVCAM-1 
may exert either a detrimental or a beneficial net effect on 
inflammatory MS disease activity, depending on the body 
region of its primary release. When released at an inflamed 
Fig. 7  Effects of sVCAM-1 on tight junction morphology are par-
tially mediated by Rho GTPase and p38 MAP kinase activation. 
Immunocytochemical analysis of F-actin (a) and occludin (b) expres-
sion in primary HBMEC which were left untreated, treated with 2 µM 
Rho-associated kinases inhibitor Y-27632 or 10 µM p38 inhibitor 
SB203580 for 2 h, 5 µg/mL sVCAM-1 for 1 h, or by one of the inhib-
itors for 2 h and additional presence of 5 µg/mL sVCAM-1 for the 
last hour. Representative of five independent experiments evaluated 
by blinded investigators. Scale bar 25 µm
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BBB where its endothelial-binding partner integrin α-4 is 
upregulated and integrin β-1 is present according to our 
study, it may further increase paracellular BBB dysfunction 
by endothelial autocrine stimulation, reflected by more Gd-
enhancing MRI lesions. When released near IFN-β injec-
tion sites, sVCAM-1 may primarily render PBMC less 
responsive to endothelium-bound VCAM-1 in active MS 
brain lesions by VLA-4 downregulation on PBMC.
Integrin α-4, which was demonstrated to be expressed by 
endothelium in MS brain lesions in this study, is the molec-
ular target of natalizumab. This humanised monoclonal 
IgG4κ antibody was approved for the treatment of severe 
relapsing–remitting MS in 2006. Therapy of MS patients 
with natalizumab reduced the number of Gd-enhancing 
MRI lesions by 92 % over 2 years in the AFFIRM trial 
[34]. This strong therapeutic effect of natalizumab most 
likely reflects its main mechanism of action in patients with 
MS, i.e. blockade of the molecular interaction between 
VLA-4 on T cells and VCAM-1 on the surface of brain 
endothelial cells, thereby strongly reducing inflammatory 
brain infiltrates [10]. Our findings, however, suggest that in 
addition natalizumab may beneficially modulate a poten-
tial detrimental interplay between integrin α-4/β-1 on brain 
endothelium and sVCAM-1 as suggested by this study.
In summary, we demonstrated that sVCAM-1 directly 
compromises the barrier function of human brain endothe-
lium by integrin α-4/β-1-mediated induction of intracellular 
signalling events. Based on these findings, we suggested a 
model of how to explain apparently contradictory findings 
on the role of sVCAM-1 in untreated versus IFN-β-treated 
MS patients. Furthermore, our results argue for a novel 
mode of action of natalizumab at the BBB, where it may 
partially protect brain endothelial cells from a sVCAM-
1-mediated barrier breakdown.
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